AIA
XPH icon

Avalon Investment & Advisory’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Avalon Investment & Advisory’s Portfolio XPH Stock Details XPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-15,052
Closed -$588K – 383
2016
Q4 		$588K Buy
+15,052
New +$613K 0.02% 276

Other funds holding XPH

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Avalon Investment & Advisory's XPH Position: Q1 2017 in Review

Avalon Investment & Advisory sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q1 2017, closing a stake of 15,052 shares — an estimated $588K sold.

Avalon Investment & Advisory first reported a position in XPH in Q4 2016 and held it in 1 quarter. The position peaked at $588K in Q4 2016. 79 funds tracked by Wall St. Rank hold XPH as of Q1 2017.

  • Avalon Investment & Advisory reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q1 2017 after selling out during the quarter.
  • Avalon Investment & Advisory sold 15,052 State Street SPDR S&P Pharmaceuticals ETF shares in Q1 2017, an estimated $588K.
  • Avalon Investment & Advisory first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q4 2016 and held it in 1 quarter.
  • Avalon Investment & Advisory's State Street SPDR S&P Pharmaceuticals ETF position peaked at $588K in Q4 2016.
  • 79 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q1 2017.

Based on Avalon Investment & Advisory's 13F filing for Q1 2017, filed 15 May 2017.